MATERIALS AND METHODS

Chemicals
1,25-(OH), D, and EB1089 [25] were kindly donated by Dr L. Binderup of LEO Pharmaceutical Products (Ballerup, Denmark). The chemical structure of EB1089 is depicted in Figure 1 . Insulin, RPMI-1640 cell culture medium, human transferrin, sodium selenite and bacitracin were purchased from Sigma Chemical Co. (St Louis, Missouri, U.S.A.). IGF-I, long R3 IGF-I and des(llS)IGF-I were obtained from GroPep Pty Ltd (Adelaide, Australia). Long R3 IGF-I is an analogue of human IGF-I synthesised in E. coli and has a substitution of an Arg for Glu at position 3 and an extension of 13 amino acids at the N-terminus [26] . Des The Netherlands). MCF-7 cells were routinely maintained in phenol red-free RPMI-1640 medium supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 p&ml streptomycin, 24 mM sodium bicarbonate (basal RPM1 medium) plus 10% FCS and 10 p&ml insulin. Prior to the start of the experiments, the cells were deprived of insulin and serum as follows: the cells were trypsinised and seeded in phenol red-free basal RPM1 medium supplemented with 2% charcoal-treated FCS (25 000 cells/cm'). The FCS was added for the attachment of the cells. After 24 h, the medium was changed to serumfree basal RPM1 medium supplemented with 2 mg/ml BSA, 10 pgiml transferrin and 30 nM sodium selenite (SFM). The medium was replaced every 2-3 days. After 1 week, the cells had grown to subconfluence and the procedure was repeated. For the experiments, cells that were cultured in SFM for several weeks were used. The experiments were started by seeding the cells in basal RPM1 medium supplemented with 2% charcoal-treated FCS. After 24 h, the medium was changed to SFM and, after another 24 h, the SFM was refreshed and the agents to be tested were added. For longterm experiments, the medium and test agents were replaced every 3 days.
Proliferation experiments
MCF-7 cells were seeded into 24-well dishes at a density of 4000 cells/cm* and incubated with the compounds to be tested as described above. After 8 days of incubation, DNA content was measured using the ethidium bromide method as described previously [7] .
Insulin and ZGF-Z binding
The insulin and IGF-I binding assay was performed as described by Maassen and associates [28] . For short-term incubations, MCF-7 cells were grown to subconfluence in SFM in six-well dishes and were subsequently exposed to the vitamin D, compounds for 24 or 48 h. For long-term incubations (8 days), the cells were exposed to the vitamin D3 compounds from the start of the experiment as described above. At the end of both the short-and long-term incubations, the cells were washed twice in PBS (pH 7.8) plus 10 mg/ml BSA. Subsequently, the cells were incubated with 3 X lO_" M ['251]insulin in PBS (pH 7.8) plus 10 mgiml BSA for 2.5 h at room temperature or with 3 X lo-" M ['251]IGF-I in PBS (pH 7.8) plus 10 mg/ml BSA and 2 mgiml bacitracin for 3.5 h at 4°C. Non-specific binding was assessed by incubating the cells with labelled insulin in the presence of 1 PM unlabelled insulin or with labelled IGF-I in the presence T. Vink-van Wijngaarden et al.
of 0.1 uM unlabelled IGF-I. After the incubation, the cells were washed 5 times with ice-cold PBS plus 1 mg/ml BSA and solubilised in 0.1 M NaOH, 0.1% SDS. The amount of bound ['251 ]insulin or ["51]IGF-I was determined in a gamma counter (NE1 600, NE Technology Ltd, Reading, U.K.) and corrected for the absorption at 260 nm, which was used as a measure for the cell number.
Assay of MAP kinase activity
MCF-7 cells were seeded (2 X 1 O4 cells/cm*) and incubated with the compounds to be tested for 5-30 min as described above. Upon activation, MAP kinase is phosphorylated. Activation of MAP kinase was detected by immunoblotting of cell homogenates as described by Van den Berghe and associates [29] . The method is based on a shift in gel electrophoretic migration owing to phosphorylation of MAP kinase.
RNA isolation and hybridisation
Cells were seeded (1.5 X lo6 cells/25 cm' flask), and incubated with the compounds to be tested as described above. Total RNA was isolated by guanidinium thiocyanate-phenolchloroform extraction and Northern analysis with lo-20 kg RNA was performed as described previously [2 11. Northern blots were hybridised with 32P-labelled human cDNA fragments specific for C-FOS [30] and GAPDH
[31]. After hybridisation, the Northern blots were washed twice in 2 X SSC, 0.1% SDS for 5 min at room temperature, twice in 2 X SSC, 0.1% SDS for 20 min at 60°C and twice in 0.5 X SSC, 0.1% SDS for 20 min at 6O'C. Membranes were exposed to medical X-ray films (Fuji Photo Film Co., Tokyo, Japan) with intensifying screens at -8O"C, and the autoradiographs were quantified using a ScanJet IIcx scanner (HewlettPackard Co., Minneapolis, U.S.A.). Before rehybridisation with GAPDH, Northern blots were washed in 5 mM Triss HCl (pH 8.0), 0.2 mM EDTA (pH 8.0), 0.05% sodium pyrophosphate and 0.1 X Denhardt's solution for at least 2 h at 65°C.
RESULTS
Inhibition of insulin-and IGF-I-stimulated growth by vitamin D, compounds
The MCF-7 cells in our laboratory are able to grow autonomously in SFM without further additions. The autonomous growth was stimulated by treatment with insulin. After 8 days of treatment, the DNA content of the wells containing SFM supplemented with insulin was 1.5-2-fold higher than the DNA content of the control wells without insulin. The insulin dose-response curve was steep, with maximum growth stimulation reached at 5 kg/ml and a median effective concentration of 1 kg/ml insulin (Figure 2 ).
The growth stimulation by 10 ng/ml insulin could be dosedependently inhibited both by 1,25-(OH),D, and the vitamin D, analogue EB1089 (Figure 3) . Based on the median effective concentration, EB 1089 was approximately 50 times more potent than 1,25-(OH)*D3 in the inhibition of insulin-stimulated growth. Both vitamin D, compounds not only reversed the growth stimulation by insulin, but also inhibited part of the autonomous growth of MCF-7 cells.
Since insulin binds not only the insulin receptor but also [PEPTIDE] (pg/ml) growth could be inhibited by the type I IGF receptor blocking antibody aIR3. The antibody inhibited the insulin-stimulated growth by 24% and IGF-I-stimulated growth by about 30%. A small inhibition of the autonomous growth (9%) was observed (data not shown). Next, we examined the mitogenic effect of IGF-I on MCF-7 cells. To avoid interference with IGF-BPS secreted by MCF-7 cells, we tested two analogues of IGF-I, long R3 IGF-I and des( l-3)IGF-I, which have reduced binding to IGF-BPS [26, 271 . Figure 2 demonstrates that MCF-7 cells respond to long R3 IGF-I with a similar increase of DNA content as obtained with insulin. The median effective concentration was 0.5 pg/ml long R3 IGF-I. Also, for des(l-3)IGF-I relatively high concentrations were needed to elicit a proliferative response. Des(l-3)IGF-I
was not active at concentrations below 1 p,g/ml (data not shown). Several studies have shown a synergistic action of insulin-IGF-I and oestradiol [32-341. However, in our culture system the mitogenic effects of insulin and the IGF-I analogues could not be sensitised by co-treatment with oestradiol (data not shown). 
10-gM EB1089
Incubations for 48 h with 1,25-(OH),D, and EB1089 (10m9 and 10m7 M) had no consistent effect on insulin or IGF-I binding (Table 1 ). In addition, we studied the effect of longterm incubations with 1,25-(OH),D, and EB1089 at timepoints where the growth inhibition by the vitamin D, compounds was observed. As shown in Table 1 , treatment with 1, 25-(OH),D, and EB1089 resulted in stimulation of insulin and IGF-I binding, by approximately 2-and 3-fold, respectively, of the control. Activation of MAI kinase is another intracellular mechanism involved in the signal transduction of growth factors [24] . We examined whether the vitamin D, compounds could affect MAP kinase activity as a mechanism for the observed inhibition of insulin-and long R' IGF-I-stimulated growth. However, in MCF-7 cells, there was no detectable activation of MAP kinase by insulin, nor by long R3 IGF-I, in a time course from 5 to 30 min. As a positive control of the assay, 10% FCS was used, which caused activation of MAP kinase after 10 min of incubation (data not shown). Although most attention has focused on the tumour promoting role of the IGFs, insulin may also play a role in the growth and development of breast turnours, acting through its own receptor [ 121. The high doses of insulin needed for growth stimulation of MCF-7 cells (EC5,, = 1 &ml) suggests that insulin was acting through the type I IGF receptor, which has a low affinity for insulin, and mimicked the effect of IGF-I. However, the small inhibition of insulin-stimulated growth by oIR3 (24% inhibition) suggests that insulin acted predominantly via the insulin receptor. In addition, the studies of Milazzo and colleagues [ 121 and Cullen and associates [14] with aIR3 suggested an involvement of the insulin receptor in the transmission of the mitogenic effect of insulin in breast cancer cells. The antibody was tested at a concentration lOOfold higher than the KD of oIR3 for binding to the type I IGF receptor in MCF-7 cells [38] . In view of the high concentrations of IGF-I needed to stimulate growth, this aIR3 concentration could still be too low, which may explain its small effect on IGF-I-stimulated growth.
Effect of the vitamin D, compounds on intracellular mediators of the insulin-IGF-I signal: C-FOS
The presence of specific insulin binding sites on MCF-7 cells was demonstrated by binding studies with [1251] insulin. Half-maximal displacement of [iz51]insulin was achieved with insulin at 300 times lower concentrations than with IGF-I. Other reports have also demonstrated the presence of functional insulin receptors on several breast cancer cell lines, including . In addition, a role of the insulin receptor in breast cancer initiation and/or progression is supported by the observations that the insulin receptor expression is increased in human breast cancer specimens and that the insulin receptor content is positively correlated with tumour grade and size [39] . Lastly, an insulin analogue with enhanced mitogenic activity increased the incidence of mammary tumours in female rats [40] .
Besides insulin, the IGF-I analogues, long R3 IGF-I and des(l-3)IGF-I, were also needed in high concentrations (0.5 &ml or more) to stimulate the growth of MCF-7 cells, whereas previous studies have shown that IGF-I and the IGF analogues can elicit a proliferative response at concentrations ranging from 1 to 50 r&ml [13, 14, 261 . There are several possible explanations for the low sensitivity of the MCF-7 cells to insulin and IGF-I, regardless of the receptor activation pathway. First, we used serum-free culture conditions, and possibly additional serum-derived factors play a synergistic role in the growth stimulation by insulin and IGF-I [32-341. Secondly, the cells could be less responsive because of the high basal growth rate. This could be due to the fact that MCF-7 cells produce autocrine acting growth factors [lo] .
To gain insight into the mechanism of the antigrowth factor activity of 1,25-(OH),D, and EB1089, we studied several aspects of the insulin and IGF-I signal transduction pathway. We also studied two intracellular responses that can be activated by insulin and IGF-I: C-FOS mRNA expression [22, 231 and MAP kinase activity [24] . The rapid induction of C-FOS mRNA expression by insulin was inhibited by 1,25-(OH),D,, indicating that C-FOS mRNA expression is a possible target for 1,25-(OH), D, and analogues in the growth inhibition of these breast cancer cells. It should be noted that the inhibition of insulin-induced C-FOS mRNA expression could already be observed at lower concentrations than the inhibition of proliferation, indicating that inhibition of only C-FOS expression is not sufficient to inhibit insulin-induced cell growth. This is supported by the observation that the vitamin D, concentration which most potently inhibited the proliferation had the weakest effect on C-FOS expression. Furthermore, a stimulation of C-FOS mRNA levels by 1,25-(OH),D, was associated with inhibition of cell proliferation in the MCF-7 cell line [36] and in the HL-60 leukaemic cell line [42] . Finally, we studied whether MAP kinase is involved in growth inhibition by 1,25-(OH),D, and EB1089. MAP kinase has been detected in a wide variety of cells and tissues and is activated by a number of growth factors (insulin, IGF-I and epidermal growth factor), hormones and other extracellular signals. Activated MAP kinase in its turn phosphorylates other proteins, including the proto-oncogene products of myc and jun, which act as transcription factors [24] . However, it appeared that MAP kinase phosphorylation was not detected, which may imply that MAP kinase is not involved in the growth stimulation by insulin and IGF-I in the MCF-7 breast cancer cells.
In conclusion, it was shown that 1,25-(OH),D, and the more potent analogue EB1089 block the mitogenic effect of insulin and IGF-I on MCF-7 breast cancer cells. It is questionable whether the observed growth inhibition of breast cancer cells by 1,25-(OH),D, and EB1089 is specific for insulin-and IGF-I-stimulated growth. Previously, we have shown that 1,25-(OH),D, also inhibits EGF-stimulated as well as oestradiol-stimulated growth [7, 2 I] . This led to the hypothesis that vitamin D3 compounds interfere with growth stimulatory agents at a late, common stage in the signal cascades leading stimulation of cell proliferation. The present observations that vitamin D, compounds also inhibit insulinand IGF-I-stimulated growth supports this hypothesis.
